Upstream & Downstream Processing

MilliporeSigma to equip ex-BMS plant in strategic partnership with Lotte

Lotte Group has named MilliporeSigma as its preferred bioprocess vendor to support its burgeoning US-based CDMO business. In May, Lotte Corporation made its first steps into the US through the acquisition of Bristol-Myers Squibb’s facility in East Syracuse, New York, bagging a manufacturing contract with the former owners as part of the deal. Now, as the Korean firm looks to set up its US-based biologics contract development and manufacturing organization (CDMO) operations, it has signed a Memorandum of Understanding (MoU)…

Invetech launches closed autologous cell therapy tech

Invetech says its Korus technology will offer industry an autologous cell therapy system that provides an option with minimal tech transfer challenges. With the Korus system launched this week, Invetech is targeting autologous cell therapy developers, including those in the CAR-T, TIL, NK, DC therapeutics areas, who are looking to start their cell therapy manufacturing process with cleaner lymphocyte or monocyte populations – and improve their overall manufacturing yield. The closed system includes elutriation and cell wash using gentle counterflow…

BPI Europe: three minutes, three Danaher tech platforms

Physical events are back with a bang and BioProcess Insider took to the exhibition floor to speak to Cytiva and Pall about their newest technologies. Technology launches have mostly been virtual over the past two years because of the COVID-19 pandemic. But as we return to standard procedure, Sushma Nayak Teichert, global product manager at Cytiva, Ignatius Gyepi-Garbrah, global product manager at Pall, and Edina Payer technical application scientist at Pall took us through what their technology does and the problems it aims…

MigVax taps Catalent to deliver COVID-19 vaccine orally

MigVax has teamed with Catalent to develop its subunit COVID-19 vaccine MigVax-101 using the CDMO’s Zydis orally disintegrating tablet (ODT) technology. Israeli crowdfunded biotech MigVax has developed an oral vaccine against COVID-19 that uses a chimeric protein to generate three kinds of simultaneous immunological responses: mucosal, blood-based, and cell-mediated immunity. To overcome delivery issues, the firm has tapped contract development and manufacturing organization (CDMO) Catalent to undertake a feasibility study to formulate MigVax-101 using its Zydis Bio orally disintegrating tablet…

High cost of complex biomanufacturing ‘a problem worth solving,’ says Waters

With the cost of manufacturing accounting for as much as 70% for cell and gene therapies, industry must look to bioprocessing efficiencies and collaboration, says Waters Corporation. Waters Corporation is an analytical instruments, software, and service company. At the firm’s 2022 investor day last week, CEO Udit Batra spoke about the difference between producing small molecules, where “you get approval to produce a product with specific chemical and physical properties,” and the present biomanufacturing landscape, where the approval is for…

MilliporeSigma pumps $470m into Ireland filtration plants

Merck Life Science – aka MilliporeSigma – will build facilities to increase filtration equipment and membrane capacity at sites in Cork, Ireland. The total investment is split between two facilities in Cork, with a new filtration manufacturing facility being built at Blarney Business Park for €150 million ($160 million) and €290 million being invested in nearby Carrigtwohill for a manufacturing plant supporting the immersion casting of membranes. From Carrigtwohill, the first commercial products will be produced in 2026. “At full…

Dover shells out $225m for bio-control instruments firm Malema

Biomanufacturing vendor Dover will bolster its Pumps & Process Solutions segment via the addition of Malema’s single-use flow sensor technology. The $225 million cash deal, expected to close in the second quarter, sees Dover add flow-measurement and control instruments maker Malema Engineering Corporation to its service offering. Malema, which is set to make approximately $40-45 million in sales in 2022, produces single-use flow sensors using Coriolis technology which it claims reduces the potential for measurement error and the need for calibration…

Cytiva opening Swiss single-use cell processing site

With work beginning weeks before the global pandemic, the plant has opened on schedule, boosting Cytiva’s capacity for single-use products aimed at supporting cell and gene therapy makers. The 7,400 m2 facility in Grens, Switzerland is set to have its official opening at the end of the month, strengthening bioprocess vendor Cytiva’s capabilities in providing single use kits for cell processing systems and their relevant consumables. The plant is ready 28 months after Cytiva – then known as GE Life…

Repligen: Robust bioprocess market will offset reduced COVID demand

Repligen has tweaked its guidance in the wake of diminishing COVID-related orders but remains positive going forward due to a “very strong order book” for its base business. For the first quarter 2022, Repligen Corporation reported record revenue of $206.4 million, 45% up on the same period last year. Despite this, the bioprocess vendor has reduced its full year guidance by 4% from $800-$830 million to $770-$800 million due to the fall in COVID-related demand, something expected to continue throughout…

Formulation lap: Sanofi turns to McLaren for manufacturing efficiency

Sanofi has teamed with Formula 1 racing team McLaren to optimise manufacturing efficiencies within its network. The multiyear deal will see Sanofi’s Industrial Affairs team benefit from McLaren Racing team’s digital and analytical expertise tto achieve excellence in manufacturing operations. “Analysis of losses, modelling and simulation of production line scheduling, and specifically product change-overs, will be key areas to maximise performance in Sanofi manufacturing sites,” McLaren said in a press release. Both Sanofi and McLaren Racing “operate in a truly…